Chung-Hsin Chen

Dr. Ch-H Chen is a distinguished urologist with expertise in urological oncology and minimally invasive surgery. He earned his M.D. from the School of Medicine at National Taiwan University (NTU), followed by a Ph.D. from NTU’s Graduate Institute of Clinical Medicine. Dr. Chen completed his urology residency at NTU Hospital in Taipei, Taiwan. His clinical focus includes urological surgery with a subspecialty in cancers of the urinary tract and prostate. Dr. Chen’s research has made significant contributions to the understanding and management of urothelial carcinoma, particularly in the upper urinary tract. His key academic work involves studying the carcinogenic role of aristolochic acid, identifying urinary biomarkers for early cancer detection, and developing advanced treatment strategies for upper tract urothelial carcinoma. He has also investigated prostate cryoablation techniques and therapeutic outcomes, as well as created predictive models for prostate cancer prognosis in Taiwan. Dr. Chen continues to integrate clinical practice with research, striving to enhance patient outcomes through innovation and evidence-based care.

15th August 2025

Time Session
15:30
17:00
Free Paper 【Podium】 (13)
Bladder UTUC (C)
Cheng-Hsi LiaoTaiwan Moderator
Chung-Hsin ChenTaiwan Moderator
TICC - 4F Joy Lounge

17th August 2025

Time Session
13:30
15:00
CaP Focal Therapy Crossfire
  • CaP Focal Therapy Crossfire
    Shin EgawaJapan Moderator
    Kai-Jie YuTaiwan Moderator
    Jacob See-Tong PangTaiwan Commenter
    Tzu-Ping LinTaiwan Facilitator
    Po-Fan HsiehTaiwan Facilitator
    Cary Nobles RobertsonUnited States Speaker Latest Clinical Data and Operative Technique on Focal One Robotic HIFU Therapy for Prostate CancerThe lecture will cover the latest clinical data and operative advancements in Focal One Robotic High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of prostate cancer. Focal One marks a significant advancement in minimally invasive, organ-sparing treatment. This technology integrates real-time MRI and ultrasound imaging with robotic precision to deliver highly focused ultrasound energy directly to cancerous prostate tissue—while minimizing damage to surrounding healthy structures.
    Chung-Hsin ChenTaiwan Speaker
    Mark EmbertonUnited Kingdom Speaker
    Peter Ka-Fung ChiuHong Kong, China Speaker Minimal Invasive Therapy: Where do We Stand in 2025Endourological, Laparoscopic and robotic surgeries have replaced most open surgeries in Urology. Emergence of new robotic platforms have provided urologists with new opportunities. Both boom-type and module-type robots have been used, and they each have their strengths in practice. Tele-surgeries have provided a new paradigm of long-distance robotic surgeries to facilitate new surgical possibilities and proctorship. State of the art robotic surgeries in retrograde intrarenal surgeries and enbloc resection MDT Discussion: Personalizing Treatment in High Volume CSPCN/ADebate: Should We Only Offer Consolidative Cytoreductive Nephrectomy in Metastatic RCC?N/AFocal Therapy in Asia – Is It Prime Time?The increase in incidence of Prostate cancer has been rapid in Asia in the past 10 years. While Robotic radical prostatectomy and Radiotherapy has been the commonest treatments for localized prostate cancer, significant long-term morbidities are observed after surgery or radiotherapy including incontinence, erectile dysfunction and irradiation injury to the bladder and rectum. In the current era of MRI-guided prostate biopsy, focal diseases can be targeted and diagnosed, and image-guided focal therapy emerged as an alternative treatment. Although Focal therapy has a relatively higher rate of local recurrence, it has the advantages of minimal or no long-term complication after treatment, and it is possible to perform retreatment with focal therapy, prostatectomy or radiotherapy. In properly selected patients, the need for salvage prostatectomy or radiotherapy after focal therapy is less than 20% at 8 years, and patients’ quality of life could be preserved. In well-selected patients, focal therapy is an attractive option. Current focal therapy for prostate cancer available in Asia includes HIFU, Cryotherapy, Targeted Microwave Ablation (TMA), irreversible electroporation (IRE) and TULSA.
    Robert NamCanada Speaker
TICC - 2F 201BC